Acceptance of high platelet reactivity as a risk factor: now, what do we do about it?

JACC Cardiovasc Interv. 2010 Oct;3(10):1008-10. doi: 10.1016/j.jcin.2010.08.011.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Aryl Hydrocarbon Hydroxylases / genetics
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Body Mass Index
  • Clopidogrel
  • Coronary Artery Disease / blood
  • Coronary Artery Disease / drug therapy*
  • Cytochrome P-450 CYP2C19
  • Genotype
  • Humans
  • Phenotype
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / pharmacokinetics
  • Platelet Function Tests
  • Polymorphism, Genetic
  • Predictive Value of Tests
  • Receptors, Purinergic P2Y12 / blood
  • Receptors, Purinergic P2Y12 / drug effects
  • Risk Assessment
  • Risk Factors
  • Ticlopidine / administration & dosage
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / pharmacokinetics

Substances

  • P2RY12 protein, human
  • Platelet Aggregation Inhibitors
  • Receptors, Purinergic P2Y12
  • Clopidogrel
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Ticlopidine